Vienna Challenge Chamber Study Using RV658 in Subjects With Allergic Rhinitis

NCT01230619 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Seasonal Allergic Rhinitis

Interventions

DRUG: RV568
DRUG: Placebo

Sponsor

Respivert Ltd